Hostname: page-component-7b7567c8c-7pwfn Total loading time: 0 Render date: 2026-11-12T10:56:53.632Z Has data issue: false hasContentIssue false

The ketamine model for schizophrenia

Published online by Cambridge University Press:  03 September 2003

Murray Alpert
Affiliation:
Department of Psychiatry, NYU School of Medicine, New York, NY 10016 murray.alpert@nyu.edu
Burt Angrist
Affiliation:
Department of Psychiatry, NYU School of Medicine, New York, NY 10016 murray.alpert@nyu.edu
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the 'Save PDF' action button.

This commentary compares clinical aspects of ketamine with the amphetamine model of schizophrenia. Hallucinations and loss of insight, associated with amphetamine, seem more schizophrenia-like. Flat affect encountered with ketamine is closer to the clinical presentation in schizophrenia. We argue that flat affect is not a sign of schizophrenia, but rather, a risk factor for chronic schizophrenia.

Information

Type
Article Commentary
Copyright
Copyright © Cambridge University Press 2003